erated safety profile.”



DOCTOR SHAWN KWATRA, M.D.

LEAD INVESTIGATOR OF OLYMPIA PROGRAM

JOSEPH W. BURNETT ENDOWED PROFESSOR AND CHAIRMAN OF DERMATOLOGY UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE










Nemluvio demonstrated long-term improvements in itch intensity, skin lesions and quality of life
The OLYMPIA LTE study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and included 508 patients from the phase II trial and the OLYMPIA 1 and 2 phase III trials.1At Week 148, in evaluable patients, the interim analysis showed that Nemluvio maintained long-term disease control with a consistent safety profile:


Over 70% of patients achieved clear or almost clear skin lesions based on Investigator’s Global Assessment score, and over 85% achieved more t
=*=*=*=*=*=
当前为第3/12页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页